<DOC>
	<DOCNO>NCT02557620</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare steady-state exposure semaglutide administer subcutaneously daily semaglutide administer subcutaneously weekly healthy subject .</brief_summary>
	<brief_title>Comparing Semaglutide Administered Subcutaneously Once Daily Semaglutide Administered Subcutaneously Once Weekly</brief_title>
	<detailed_description />
	<criteria>Male female , age 1855 year ( inclusive ) time sign informed consent Considered generally healthy base medical history , physical examination , result vital sign , ECG clinical laboratory test perform screeningvisit , judge investigator Body mass index ( BMI ) 20.0 29.9 kg/m^2 ( inclusive ) HbA1c ( glycosylated haemoglobin ) 6.5 % Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method throughout trial include 5 week followup period ( adequate contraceptive measure require local regulation practice ) Any disorder investigator 's opinion might jeopardise subject 's safety , evaluation result , compliance protocol History pancreatitis ( acute chronic ) Screening calcitonin equal 50 ng/L Family personal history Multiple Endocrine Neoplasia Type 2 ( MEN2 ) Medullary Thyroid Carcinoma ( MTC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>